Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Oxaliplatin/5-FU Chemoradiation in Rectal Cancer
NCT00831181Phase 2Completed
- Sponsor
- Mount Sinai Beth Israel
- Start
- Jul 2004
- Primary completion
- Nov 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by Mount Sinai Beth Israel. Primary endpoint: Pathologic Complete Response. Started Jul 2004; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00831181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831181.